Co-Authors
This is a "connection" page, showing publications co-authored by Franck Touret and Xavier de Lamballerie.
Connection Strength
2.924
-
Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium. mBio. 2021 08 31; 12(4):e0085021.
Score: 0.955
-
Of chloroquine and COVID-19. Antiviral Res. 2020 05; 177:104762.
Score: 0.870
-
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Res. 2021 09; 193:105137.
Score: 0.239
-
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020 08 04; 10(1):13093.
Score: 0.224
-
Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone. Emerg Microbes Infect. 2018 Sep 26; 7(1):161.
Score: 0.197
-
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun. 2021 03 19; 12(1):1735.
Score: 0.058
-
SARS-CoV-2 viral dynamics in non-human primates. PLoS Comput Biol. 2021 03; 17(3):e1008785.
Score: 0.058
-
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020 09; 585(7826):584-587.
Score: 0.056
-
Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? Viruses. 2020 07 07; 12(7).
Score: 0.056
-
Prolonged Infectivity of SARS-CoV-2 in Fomites. Emerg Infect Dis. 2020 09; 26(9).
Score: 0.056
-
Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples. Viruses. 2020 06 08; 12(6).
Score: 0.055
-
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. Clin Pharmacol Ther. 2020 08; 108(2):188.
Score: 0.055
-
Complete Coding Sequences of Two Dengue Virus Type 2 Strains Isolated from an Outbreak in Burkina Faso in 2016. Genome Announc. 2017 Apr 27; 5(17).
Score: 0.045